<?xml version="1.0" encoding="UTF-8"?>

<Task xmlns="http://hl7.org/fhir">
  <id value="PGxRecEx02"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/task-rec-followup"/>
  </meta>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title="Codes: {http://loinc.org LA26421-0}">Consider alternative medication</span></p><p><b>description</b>: voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.</p><p><b>for</b>: <a href="Patient-CGPatientExample01.html">Generated Summary: Medical Record Number: m123 (USUAL); Adam B. Everyman ; gender: male; birthDate: 1951-01-20</a></p><p><b>reasonReference</b>: <a href="Observation-TxImp02.html">Poor metabolizer. Generated Summary: <span title="Codes: {http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span>; <span title="Codes: {http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/TbdCodes therapeutic-implication}">Therapeutic Implication</span></a></p></div>
  </text>
  <status value="requested"/>
  <intent value="proposal"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA26421-0"/>
      <display value="Consider alternative medication"/>
    </coding>
  </code>
  <description value="voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/."/>
  <for>
    <reference value="Patient/CGPatientExample01"/>
  </for>
  <reasonReference>
    <reference value="Observation/TxImp02"/>
    <display value="Poor metabolizer"/>
  </reasonReference>
</Task>